Germany Drug Delivery Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The germany drug delivery devices market size was valued at USD 10.45 billion in 2025 and estimated to grow from USD 11.35 billion in 2026 to reach USD 17.18 billion by 2031, at a CAGR of 8.64% during the forecast period (2026-2031). This report is Segmented by Device Type (Injectable Delivery Devices, Transdermal Patches, Infusion Pumps, and More), Route of Administration (Injectable, Inhalational, Transdermal, and More), Application (Diabetes, Oncology, Cardiovascular, and More), and End Users (Hospitals, Ambulatory Surgical Centres, Homecare Settings, and More). The Market and Forecasts are Provided in Terms of Value (USD).

Germany Drug Delivery Devices Market Trends and Insights

High Prevalence and Incidence of Chronic and Infectious Diseases

Germany reports higher-than-EU-average prevalence for diabetes (8.4%), cardiovascular diseases (6.8%), and chronic respiratory diseases (11.4%). This chronic-disease load drives steady demand for advanced injectors, insulin pens, smart pumps, and sustained-release implants that improve adherence and outcomes. Diabetes alone is projected to affect 10.9-14.2 million Germans by 2040, pushing continuous upgrades in automated insulin delivery ecosystems. Oncology demand follows a similar path: micro-/nano-robots under development at the German Cancer Research Center aim to raise tumour-site uptake while cutting systemic toxicity. Together, disease trends and research breakthroughs keep the Germany drug delivery devices market on an innovation-driven trajectory.

Growing Trend of Home Healthcare and Aging Population

People aged ≥ 65 will rise from 21% of the population in 2023 to nearly 30% by 2050. Concurrently, those requiring long-term care could climb to 14 million by 2050. These shifts amplify the need for devices that non-professionals can use safely in domestic settings. On-body injectors such as Gerresheimer’s Gx SensAir® allow weekly subcutaneous dosing of monoclonal antibodies without clinical visits, cutting travel-related emissions and easing caregiver burdens. Consumer familiarity with telehealth platforms further accelerates uptake of connected inhalers, pens, and patches that integrate adherence dashboards, reinforcing market momentum in Germany drug delivery devices market.

Stringent Regulatory Requirements and Product Recalls

Germany enforces EU Medical Device Regulation (MDR) alongside its Medical Device Law Implementation Act. Combination products must satisfy dual drug-device evidence packages, and higher-risk classes require third-party conformity assessments.Resulting cost spikes and recall liabilities weigh heaviest on SMEs, occasionally pausing launches and trimming the Germany drug delivery devices market growth curve.

Other drivers and restraints analyzed in the detailed report include:

• Increasing Investment in Biosimilar and Biologics Product Innovation and Development
• Government Initiatives Supporting Fast Track Approval and Reimbursement

Segment Analysis

Injectable devices represented 43.02% of all revenues in 2025, cementing their role in the Germany drug delivery devices market size. Sustained demand arises from biologic therapies that dominate new drug approvals and from continuing preference among clinicians for parenteral accuracy. SCHOTT Pharma’s capacity surge in polymer and glass syringes underscores industry confidence.

Implantable pumps, micro-chips, and bioresorbable depots post the quickest gains at an 9.96% CAGR. Patient-friendly inhalers preserve share amid a high national burden of chronic respiratory illness, while transdermal patches earn incremental adoption for hormone and pain management. Across categories, embedded connectivity features enhance dose logging and feedback loops, lifting adherence and data-driven care pathways within the Germany drug delivery devices market.

Injectable delivery retained a 49.21% revenue stake in 2025, reflecting clinician trust in intravenous, subcutaneous, and intramuscular routes for vaccines and large-molecule drugs. This proportion anchors the Germany drug delivery devices market share and is bolstered by next-gen autoinjectors that lower activation force and support 2-5 mL volumes.

Transdermal formats scale fastest at a 9.81% CAGR on the back of microneedle arrays and wirelessly powered acoustic patches that raise payload size limits. Oral mucosal films gain traction for rapid pain relief, while inhaled, ocular, and nasal modalities extend options for targeted local therapy, together enriching clinical toolkits available to practitioners in the Germany drug delivery devices market.

Complete Report Scope:

• By Device Type
  • Injectable Delivery Devices
  • Inhalation Delivery Devices
  • Infusion Pumps
  • Transdermal Patches
  • Implantable Drug Delivery Systems
  • Ocular Inserts & Delivery Implants
  • Nasal & Buccal Delivery Devices
• By Route of Administration
  • Injectable
  • Inhalation
  • Transdermal
  • Oral Mucosal (Buccal and Sublingual)
  • Ocular
  • Nasal
• By Application
  • Diabetes
  • Oncology
  • Cardiovascular
  • Respiratory
  • Central Nervous System Disorders
  • Infectious Diseases
  • Others
• By End-user
  • Hospitals
  • Ambulatory Surgical Centres
  • Homecare Settings
  • Clinics and Speciality Centres
  • Others

List of Companies Covered in this Report:

• Beckton Dickinson
• Gerresheimer
• Ypsomed
• Bayer
• Boehringer Ingelheim
• Pfizer
• Solventum
• Phillips-Medisize LLC
• Novartis
• Owen Mumford
• Novo Nordisk
• Medtronic
• West Pharmaceutical Services
• SCHOTT
• Haselmeier GmbH
• Sanofi
• Terumo
• Teva Pharmaceutical Industries
• Vetter Pharma-Fertigung GmbH & Co. KG
• Nemera La Verpilliere SAS

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support